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Abstract
A number of reports indicated that Aurora-A or Aurora-B overexpression represented a neg-
ative prognostic factor in several human malignancies. In thyroid cancer tissues a deregu-
lated expression of Aurora kinases has been also demonstrated, butno information
regarding its possible prognostic role in differentiated thyroid cancer is available. Here, wee-
valuated Aurora-A and Aurora-B mRNA expression and its prognostic relevance in a series
of 87 papillary thyroid cancers (PTC), with a median follow-up of 63 months. The analysis of
Aurora-A and Aurora-B mRNA levels in PTC tissues, compared to normal matched tissues,
revealed that their expression was either up- or down-regulatedin the majority of cancer tis-
sues. In particular, Aurora-A and Aurora-B mRNA levels were altered, respectively, in 55
(63.2%) and 79 (90.8%) out of the 87 PTC analyzed.A significant positive correlation be-
tween Aurora-A and Aurora-B mRNAswas observed (p=0.001). The expression of both Au-
rora genes was not affected by the BRAFV600E mutation. Univariate, multivariate and
Kaplan-Mayer analyses documented the lack of association between Aurora-A or Aurora-B
expression and clinicopathological parameterssuch as gender, age, tumor size, histology,
TNM stage, lymph node metastasis and BRAF status as well asdisease recurrences or
disease-free interval. Only Aurora-B mRNA was significantly higher in T(3-4) tissues, with
respect to T(1-2) PTC tissues. The data reported here demonstrate that the expression of
Aurora kinases is deregulated in the majority of PTC tissues, likely contributing to PTC pro-
gression. However, differently from other human solid cancers, detection of Aurora-A or
Aurora-B mRNAs is not a prognostic biomarker inPTC patients.
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Introduction
The incidence of differentiated thyroid cancers (DTC) has been increasing over the last de-
cades, mainly due to the increasing ability to diagnose malignant transformation in small non-
palpable nodules [1–4]. DTC comprise two main histological entities, the rare follicular thyroid
carcinoma (FTC) and themore common papillary thyroid carcinoma (PTC). Following dedif-
ferentiation DTCare assumed to generate poorly DTC (PDTC) and highly aggressive anaplastic
thyroid carcinomas (ATC) [5–6]. Relevant molecular alterations encountered in thyroid cancer
progression comprise gene rearrangements of tyrosine kinase receptors, such as the RET/PTC
and NTRK1, activating point mutations of the RAS and BRAF genes, and the oncogenic fusion
protein PAX8-PPARγ [7].
The prognosis of DTC patients is usually favorable, with a 10-year-survival rate for approxi-
mately 90% of them. Nonetheless, about 20% of patients face disease recurrence and DTC-
related deaths [8]. The stratification and prognosis of DTC patients rely on clinicopathological
variables such as the patient’s age, tumor size, histology, lymph nodal or distant metastasis [8–
11]. These parameters, however, are capable of providing only a rough prediction of the disease
outcome, placing patients with very different disease-specific progression and survival times
within the same risk group. Similarly, they fail to predict the risk of cancer recurrence. There-
fore, the identification of new prognostic molecular biomarkers able to testify tumor aggres-
siveness is required [11–17].
The genetic instability leading to cell aneuploidy and transition to more aggressive pheno-
types represents a hallmark of solid cancers including thyroid carcinomas [18–22].In fact, the
number and the frequency of chromosomal abnormalities observed in thyroid cancers increase
from DTC to PDTC and ATC [5, 20]. Different mitotic kinases, whose expression or function
has been found altered in cancer cells, are held responsible for tumor genetic instability. These
include the three Aurora kinase family members, Aurora-A, -B and -C, implicated in the regu-
lation of multiple aspects of chromosome segregation and cytokinesis [23]. During the cell
cycle, their expression is closely regulated, being maximal in the G2/M phase, while their rapid
degradation at the end of mitosis by the ubiquitin-proteasome pathway is required to permit
the cell to enter into a new cell cycle [23]. Aurora-A localizes onto the duplicated centrosomes
and is involved in mitotic entry, centrosome and spindle maturation, while Aurora-B associates
with chromatin where it forms the so-called chromosomal passenger complex (CPC) with
other proteins such as INCENP, survivin and borealin, participating in chromosome condensa-
tion [23]. Moreover, during the transition from anaphase to telophase, Aurora-B plays a role in
mitotic spindle dynamics, connections of chromosomes to spindle microtubules, and cleavage
furrow. Aurora-C is expressed mainly in testis and, similarly to Aurora-B, it has been shown to
join the CPC in mitotic cells [23]. Given the crucial tasks of Aurora kinases in all mitotic stages,
their dysfunction and/or dysregulation are held responsible, at least in part, for the abnormal
cell divisions and aneuploidy observed in malignant cells. In agreement with this, overexpres-
sion of Aurora-A and/or Aurora-B has been shown to associate with a poor prognosis in sever-
al human malignancies, including breast, gastric, prostate, head and neck, bladder, ovarian,
colon, adrenocortical and lung cancers [24–31].
Data from our own and other research groups previously showed an altered expression of
Aurora kinases in different thyroid cancer derived cell lines and tissues [32–35]. Although
these kinases are now emerging as promising new therapeutic targets for thyroid cancer treat-
ment, no attempt has been madeso far to evaluate the possible prognostic value of Aurora ki-
nases in PTC patients [23, 36–39]. In the present studywe evaluated, by means of quantitative
RT-PCR, the expression level of Aurora-A and Aurora-B in a case study of 87 PTC tissues
matched against normal tissues. Data were then correlated with the clinicopathological
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parameters and with the disease-free interval of patients. In addition, since the BRAFV600E mu-
tation, the most frequently encountered alteration in PTC, was recently shown to induce the
expression of Aurora-B in melanoma cells, the effects of the BRAF mutation on the expression
of Aurora kinases in PTC tissues was also evaluated [40].
Materials and Methods
Tissue samples, histology and patient’s staging
The case study included 87 consecutive patients; normal and matched tumor thyroid tissues
were obtained from surgical specimens of 19 males and 68 females (age range 11–83 yrs, median
44.21yrs) who underwent total thyroidectomy for PTC in the Department of Surgical Sciences,
“Sapienza”University of Rome (n = 31), or in the Department of Medical and Surgical Sciences,
University of Padua, Italy (n = 56).All patients gave their written informed consent. For three
underage patients the written informed consent was obtained from their parents. The study was
approved by the Policlinico Umberto I hospital ethical committee (Ref. 2615). Tissue samples
were collected, frozen in liquid nitrogen and stored at −80°C. Of the 87 PTC patients, 76 exhib-
ited the classical, 10 the follicular, and 1 the tall cell variant. Two different histopathologists
made the histological diagnoses independently according to theWorld Health Organization
classification and in blind manner with respect to Aurora kinase expression [41]. At the time of
surgery, lymph node metastases were found in 38 patients. Following TNM staging, 54 patients
were identified as being at stage I, 1 at stage II, 25 at stage III and 7 at stage IV. Forty to fifty days
after surgery, all patients underwent radioiodine therapy and the subsequent whole body scan
(WBS) showed the absence of metastases. Patients then started thyroid hormone replacement
therapy. To ascertain their disease-free condition, 4 to 5 months later all the patients underwent
neck ultrasound and serum thyroglobulin (Tg) measurement. Recurrences were diagnosed by
fine-needle aspiration (FNA) cytology, 131I WBS or histological analysis following surgical resec-
tion of the lesion. Of the 87 patients, the follow-up (median 63months, range 8-133months) was
available for 78 (18 males and 60 females with a median age of 44yr), 52of whom were at TNM
stage I-II and the remaining 26 at stage III-IV. The lower limit of times-to-recurrence started at
6 months. During the follow-up 21 recurrences were recorded, 17 being cervical lymph nodes,
diagnosed by FNA cytology, and 4 lung metastases, diagnosed byWBS.
Determination of BRAFV600E mutation
Genomic DNA was extracted from the frozen tissues using the DNeasy Blood and Tissues kit
according to the manufacturer’s protocol. The BRAF status of exon 15 was assessed by both di-
rect sequencing and mutant allele-specific PCR amplification for the T to A substitution at nu-
cleotide 1799 (V600E), using the procedure previously describedand in blind manner with
respect to Aurora kinase expression[42].
PCCL3 cell culture
The well-differentiated, non-transformed rat thyroid epithelial cell line PCCL3 was a gift from
Dr. J.A. Fagin (Memorial Sloan-Kettering Cancer Center, New York). The cells were propagated
in H4 complete medium consisting of Coon’s medium/F12 high zinc supplemented with 5%
fetal bovine serum, 0.3 mg/ml L-glutamine, 1 mIU/ml TSH, 10 μg/ml insulin, 5 μg/ml apo-
transferrin, 10 nM hydrocortisone, and penicillin/streptomycin. These cells conditionally
express BRAFV600E in a doxycycline-dependent manner [43]. The BRAFV600E induction was ob-
tained by adding to H4 complete medium doxycycline 1 μg/ml, and incubating the cells for 48 h.
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Extraction and analysis of mRNA
The thyroid tissues were homogenized with the ultra-turrax, and total RNA was extracted from
the tissues or PCCL3 cells applying the acid guanidinium thiocyanate—phenol—chloroform
method [44]. The first cDNA strand was synthesized from 5 μg of RNA with M-MLV reverse
transcriptase and anchored oligo(dT)23 primers (Sigma Chemicals Co.). Parallel controls for
DNA contamination were carried out omitting the reverse transcriptase. The templates ob-
tained were used for quantitative PCR amplifications of the Aurora kinases and housekeeping
genes employing the LightCycler instrument (Roche Diagnostics, Mannheim, Germany), the
SYBR Premix Ex Taq II (TliRNase H Plus) (Takara, Otsu, Shiga, Japan) and specific primers
listed in Table 1. Amplicon specificities were checked by automated DNA sequencing (Primm,
San Raffaele Biomedical Science Park, Milano, Italy), evaluation of melting temperatures, and/
or electrophoresis on 2% agarose gel containing ethidium bromide. Standard curves for all
genes were achieved with five-fold dilutions of PCCL3 cells or mixed human thyroid tissue
cDNA. Calculation of data for human thyroid tissues was performed by the Relative Expression
Software Tool (REST 2009) using a normalization factor (NF) computed as the geometric
media of 3 reference genes (GAPDH, RPL13A and SDHA), as previously described [45, 46].
The fold change of Aurora kinase expression for each tumor sample was referred to its normal
counterpart. This analysis was performedin blind manner with respect to histological and clini-
cal data of the patients. Fold variations between 0.8 and 1.2 were considered unchanged. Calcu-
lations of the data for the experiments on PCCL3 cells were carried out using the LightCycler
relative quantification software 1.0 (Roche Diagnostics), and the fold expression of Aurora ki-
nases for doxycycline-treated PCCL3 cells was normalized against non-treated cells. All the re-
sults are reported as mean±SEM and median values.
Statistical analysis
The non-parametric MannWhitney test was used to calculate the statistical significance of dif-
ferences in the expression levels of Aurora kinases in PTC with deregulated expression versus
PTC with unchanged mRNA levels, and in wild type versus mutated BRAF samples. In addi-
tion, the association of the expression of Aurora kinases with gender, histology, lymph node
metastasis, TNM stage or recurrences was evaluated by the MannWhitney test. The analyses
of the correlation between Aurora-A and Aurora-B mRNAs levels, as well as between these
and age were performed using the Rho Spearman test. To assess the independent association of
Aurora kinases with DFI, the Cox regression text was applied. The impact of Aurora kinase ex-
pression on the disease-free interval (DFI) was assessed by means of Kaplan-Meier analysis
Table 1. Sequences, genomic positions, and amplicon sizes of the primers used in qRT-PCR for the target and reference genes.
Gene Primers Exon Size (bp)
Human Aurora-A Forward 50-TTGGAAGACTTGGGTCCTTG-30 Reverse 50-TGGAGCTGTAGCCTTAACAGG-30 1 2–3 211
Human Aurora-B Forward 50-AAAGAGCCTGTCACCCCATC-30 Reverse 50-CGCCCAATCTCAAAGTCATC-30 3 5 155
Human GAPDH Forward 5’-ATCATCAGCAATGCCTCCTG-3’ Reverse 5’-GGCCATCCACAGTCTTCTG-3’ 6–7 8 136
Human RPL13A Forward 5’-ACCGTGCGAGGTATGCTG-3’ Reverse 5’-TAGGCTTCAGACGCACGAC-3’ 4–5 6 148
Human SDHA Forward 5’-GCATAAGAACATCGGAACTGC-3’ Reverse 5’-GGTCGAACGTCTTCAGGTG-3’ 12 13 147
Rat Aurora-A Forward 50-TGCTGCTTGGCTCAAATG-30 Reverse 50-TCCGACCTTCAATCATCTCC-30 10 11 105
Rat Aurora-B Forward 50-ACATAAAGCCCGAGAACCTG-30 Reverse 50-ATCCGCCCTTCAATCATCTC-30 2 3 145
Rat GAPDH Forward 50-AACCCATCACCATCTTCCAG-30 Reverse 50-GGAGATGATGACCCTTTTGG-30 4 5 147
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RPL13A, ribosomalprotein L13a; SDHA, succinatedehydrogenasecomplex, subunit A.
doi:10.1371/journal.pone.0121514.t001
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combined with Mantel-Cox log-rank. For the Kaplan-Meier analysis, Aurora kinase values
were divided into three groups based on increased, unchanged or decreased kinase expression.
All statistical analyses were carried out using the version 8.0 of the Stata software (Stata Corpo-
ration 2003, College Station, Tx). Results were considered significantly different if p values
were lower than 0.05.
Results
Expression of Aurora kinases in papillary thyroid cancer (PTC) tissues
The analyses of Aurora-A and Aurora-B mRNA levels in PTC tissues, compared to their nor-
mal matched tissues,revealed that Aurora-A mRNA levelswere deregulated in 55 (63.2%) out
of 87 PTC samples, with an increase in 30 and a decrease in 25 (Fig. 1A). Aurora-B mRNA lev-
els were altered in 79 (90.8%) out of 87 samples, being up-regulated in 57 and down-regulated
in 22 (Fig. 1B) of the cases. As reported in Fig. 1C, mRNA levels of Aurora-A and Aurora-B
were positively correlated to each other (p = 0.001).
BRAFV600E mutation and Aurora kinase expression in PTC tissues
To assess the effect of BRAFV600E mutation on the expression of Aurora-A and Aurora-B we
first analyzed the mRNA level of both genes in BRAFV600E PTC tumors (n = 37), compared
with those harboring the wild type protein (n = 38) (Fig. 2A). The results showed that thepre-
sence of the BRAFV600Emutation did not affect the expression levels of Aurora-A or Aurora-B
in PTC tissues, compared with the wild-type BRAF PTC tissues. To corroborate these in vivo
observations, we performed in vitro experiments on the well-differentiated, non-transformed
rat epithelial cell line PCCL3, characterized by a doxycycline-dependent BRAFV600E expression
system [50]. In these cells the BRAFV600E expression and subsequent induction of the MEK/
ERK phosphorylation pathway appeared 12 h after the addition of doxycycline, and the total
BRAF expression (endogenous wild-type + induced V600E mutant) at 48 h was estimated to
be 2-fold greater than the control. As reported in Fig. 2B, the treatment of PCCL3 with doxycy-
cline (1 μg/ml for 48 h) did not affect Aurora kinase mRNA levels.
Prognostic relevance of Aurora kinase expression in PTC patients
Variations in the expression of Aurora-A did not associate with any of the clinicopathological
parameters analyzed (Table 2) while apositive correlation (p<0.001) was found between
Aurora-B mRNA levels and tumor size (Table 2).The Kaplan-Meier analysis demonstrated no
correlation between patients’ disease-free interval and Aurora kinase up- or down-regulation
(Fig. 3). Multivariate analysis showed that increased or reduced expression of Aurora-A or
Aurora-B, TNM stage, age or the BRAFV600E mutation failed to predict disease outcome
(Table 3). Only females showed a statistically significant reduction of the hazard ratio (HR
0.286) for disease recurrences (Table 3).
Discussion
In previous studies, our and other research groups demonstrated a deregulated expression of
Aurora kinases in differentiated and anaplastic thyroid cancer tissues [23]. This was confirmed
in the present study where Aurora-A and Aurora-B gene expression was found either up-
regulated or down-regulated (63.2% and 90.8%, respectively) in the majority of the papillary thy-
roid cancer (PTC) tissues analyzed, compared to their normal matched thyroid tissues. It is
worth mentioning that either the up-regulation or down-regulation of Aurora kinases may
prove proliferatively advantageous to thyroid cancer cells. In fact, different reports demonstrated
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Fig 1. Expression of Aurora kinases in 87 papillary thyroid cancer tissues. A and B) Variations in the
expression of Aurora-A and Aurora-B in papillary thyroid cancer tissues. The fold changes were calculated
considering the Aurora-A or Aurora-B mRNAs levels observed in normal matched thyroid tissue equal to 1.
The statistical evaluation of the data was performed usingthe non-parametric Mann-Whitney test. The small
bars in the graph indicate the median values. C) Correlation analysis of Aurora-A and Aurora-B mRNAs in
PTC tissues. The data were evaluated by applying the Rho Spearman test.
doi:10.1371/journal.pone.0121514.g001
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Fig 2. Lack of effects of BRAFV600E on the expression of Aurora kinases. A) Expression of Aurora-A and Aurora-B in papillary thyroid cancer tissues with
wild type (n = 38) or mutated BRAF (n = 37). The fold changes were calculated considering the Aurora-A or Aurora-B mRNAs level observed in normal
matched thyroid tissue equal to 1. The statistical evaluation of the data was performed by applying the non-parametric MannWithney test. The small bars in
the graph indicate the median values. B) Effect of BRAFV600E on Aurora kinases mRNAs in PCCL3 cells. The latter were induced to express BRAFV600E in a
doxycycline-dependent manner. The fold changes of Aurora kinase mRNA were normalized against the non-treated cells.
doi:10.1371/journal.pone.0121514.g002
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that the amount of Aurora-A proteinin the centrosome is critical for its replication and mitotic
functions, and that either a lack or excess of Aurora-Acan lead to abnormal mitosis as well as to
chromosome segregation and cytokinesis defects [47].
It has recently been shown that in melanoma cells the expression of Aurora-B andWee1-
like protein kinase are induced by the presence of BRAFV600E[40]. Since BRAFV600E mutation
is frequently encountered in PTC,we also sought to determine whether the mutation in thyroid
cancer cells was associated to increased expression of Aurora kinases. In our series, the BRAF
status was assessed in 75 PTC tissues and BRAFV600E was found in 37 (49.3%)of them. Howev-
er, no difference in Aurora-A or Aurora-B expression levelswas found between wild type and
BRAFV600E PTC tissues. These observations were confirmedby in vitro experiments on rat thy-
roid PCCL3 cells, expressing the BRAFV600E in a doxycycline dependent manner [43]. In fact,
the treatment of these cells with doxycycline did not affect the expression level of either
Aurora-A or Aurora-B.
Over the last decade, a number of reports indicated that the overexpression of Aurora-A or
Aurora-B represents a negative prognostic factor in several human malignancies, including
breast, gastric, prostate, head and neck, bladder, ovarian, colon, adrenocortical and lung can-
cers[25–32]. Fewer studies, however, associated the overexpression of Aurora-A or Aurora-B
with a favorable prognosis in colorectal, gastric and ovarian carcinomas [48–50]. To date, no
information regarding the possible prognostic role of Aurora kinases in differentiated thyroid
cancer has been reported. In this context, we here evaluated the prognostic relevance of
Aurora-A and Aurora-B mRNA levels in a series of 78 PTC, with a median follow-up of
Table 2. Univariate statistical analysis of Aurora-A and Aurora-B expression and clinicopathological parameters in 87 PTC patients.
Aurora-A P value Aurora-B P value
Gender
Male (n = 19) 1.93±0.62 0.463 4.33±1.35 0.423
Female (n = 68) 1.62±0.43 3.08±0.42
Age (years) Corr. Coeff. 0067 0.537 Corr. Coeff. 0.024 0.823
Histology
Classic variant (n = 76) 1.68±0.39 0.285 3.35±0.47 0.946
Other variants (n = 11) 1.79±1.13 3.15±1.04
BRAF
Wild type (n = 38) 1.94±0.74 0.596 2.33±0.349 0.165
V600E (n = 37) 1.43±0.34 4.31±0.923
Tumor size
T(1–2) 1.80±0.79 0.366 1.63±0.24 <0.001
T(3–4) 1.60±0.29 4.51±0.68
Lymphnode metastasis
No (n = 49) 1.89±0.60 0.383 2.95±0.371 0.906
Yes (n = 38) 1.41±0.30 3.87±0.89
TNM Stage
I-II (n = 55) 1.29±0.24 0.200 2.89±0.39 0.271
III-IV (n = 32) 2.36±0.89 4.14±0.99
Recurrences
No (n = 57) 1.68±0.45 0.692 3.35±0.54 0.203
Yes (n = 21) 1.70±0.76 3.14±0.75
Corr. Coeff.: correlation coefficient.
doi:10.1371/journal.pone.0121514.t002
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63 months. Univariate analyses documented the lack of association between Aurora-A expres-
sion and clinicopathological parameters,including age, gender, tumor size, lymph node metas-
tasis, histology, TNM, BRAF status and recurrences. Similarly, Aurora-B expression did not
correlate with any of these parameters with the exception of tumor size, in which mRNA levels
Fig 3. Aurora kinasemRNA levels and disease-free interval (DFI) in papillary thyroid cancer patients.
Kaplan-Meier analysis combined with Mantel-Cox log-rank statistical test performed on 75 PTC patients
followed-up from 8 to 133 months.
doi:10.1371/journal.pone.0121514.g003
Aurora Kinases Are Not Prognostic Biomarkers in PTC Patients
PLOS ONE | DOI:10.1371/journal.pone.0121514 March 25, 2015 9 / 13
were significantly higher in T(3–4) tissues, with respect to T(1–2) tissues. Kaplan-Meyer and
multivariate analyses confirmed that deregulated expression of Aurora kinases is not a prog-
nostic biomarker of papillary thyroid cancer patients. In multivariate analysis female sex
showed a significant protective effect (Hazard Ratio 0.286, p = 0.021). The latter is in agree-
ment with two recent studies performed on large case-series showing the protective role of the
female gender on disease-specific survival[51, 52].It has to be mentioned that a limit of the
present study is the relative low number of patients analyzed which provide a statistical power
(1-β) of 0.63.
Conclusions
In conclusion, although the data reported hereneed to be confirmed by means of larger case-
studies, they demonstrated that the expression of Aurora kinases is deregulated in the majority
of PTC tissues, and probably contributes to PTC progression and cancer cell aneuploidy. How-
ever, differently from other human solid cancers, Aurora-A or Aurora-B expression at the
mRNA level is not a prognostic biomarker in the case of PTC patients.
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